PROSPECTIVE, MULTICENTER RANDOMIZED GITMO/IIL TRIAL COMPARING INTENSIVE (R-HDS) VERSUS CONVENTIONAL CHEMOIMMUNOTHERAPY (CHOP-R) IN HIGH-RISK FOLLICULAR LYMPHOMA AT DIAGNOSIS: THE SUPERIOR MOLECULAR REMISSION (MR) RATE OF R-HDS EXPLAINS ITS BETTER CLINICAL PERFORMANCE